2024
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Wiseman A, Alhamad T, Alloway R, Concepcion B, Cooper M, Formica R, Klein C, Kumar V, Leca N, Shihab F, Taber D, Mulnick S, Bushnell D, Hadi M, Bunnapradist S. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Annals Of Transplantation 2024, 29: e943498-1-e943498-13. PMID: 38526543, PMCID: PMC10944009, DOI: 10.12659/aot.943498.Peer-Reviewed Original ResearchConceptsLCP-tacrolimusImmediate-release tacrolimusKidney transplantationFirst-line optionKidney transplant recipientsRandomized clinical trialsDe novo settingTacrolimus formulationReview available dataEvidence-based recommendationsTrough levelsOnce-dailyTransplant recipientsClinical decision-makingOptimal doseClinical trialsExpert cliniciansConsensus statementTransplant expertsStrength of evidenceClinical practiceKidneyTacrolimusDe novoDelphi consensus survey
2013
Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients
Heavner MS, Tichy EM, Yazdi M, Formica RN, Kulkarni S, Emre S. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. American Journal Of Health-System Pharmacy 2013, 70: 1507-1512. PMID: 23943182, DOI: 10.2146/ajhp120783.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsBrand-name tacrolimusTrough tacrolimus levelsTransitions of careTransplant recipientsAcute rejectionTacrolimus levelsTacrolimus dosageHospital admissionBiopsy-proven acute rejectionSingle-center observational studyTacrolimus trough levelsMonths of dischargePercentage of patientsMeeting study criteriaPeriod of careGeneric tacrolimusKidney transplantTrough concentrationsTrough levelsClinical outcomesDosage adjustmentGeneric formulationStudy criteriaObservational study